HeyJaredCaleb Rans
- Indexed articles, last 90 days
- 17
- Latest publication
- Sep 30, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Jul 7, 2026
Latest articles
New Tool Detects Endometrial Cancer With ‘Excellent Diagnostic Accuracy’ - Oncology Nurse Advisor (opens the original)
Read excerpt
A minimally invasive diagnostic tool comprising urine and vaginal cytology accurately detects high-grade or advanced endometrial cancer in women with postmenopausal bleeding, according to research published in The Lancet Obstetrics, Gynaecology, & Women’s Health. “Postmenopausal bleeding prompts urgent investigation with sequential invasive and costly tests that can be painful and distressing for women,” study researchers pointed out. “A simple noninvasive test to identify cancer and safely reas
New Tool Detects Endometrial Cancer With ‘Excellent Diagnostic Accuracy’ (opens the original)
Read excerpt
A minimally invasive diagnostic tool comprising urine and vaginal cytology accurately detects high-grade or advanced endometrial cancer in women with postmenopausal bleeding, according to research published in The Lancet Obstetrics, Gynaecology, & Women’s Health. “Postmenopausal bleeding prompts urgent investigation with sequential invasive and costly tests that can be painful and distressing for women,” study researchers pointed out. “A simple noninvasive test to identify cancer and safely reas
REZILIENT3: Adding Zipalertinib to Chemo Improves PFS in EGFR Exon20ins+ NSCLC - Oncology Nurse Advisor (opens the original)
Read excerpt
Adding zipalertinib to chemotherapy improves progression-free survival (PFS) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins), according to findings presented at the 2026 World Conference on Lung Cancer. The tyrosine kinase inhibitor zipalertinib in combination with platinum-based chemotherapy is a new and highly efficacious option for frontline treatment of metastatic EGFR ex20ins-mutant NSCLC, said study pre
Amivantamab Plus Chemo Bests Chemo Alone in Advanced EGFR Ex20ins NSCLC - Oncology Nurse Advisor (opens the original)
Read excerpt
Adding amivantamab to first-line chemotherapy improves overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion (ex20ins) mutations, according to research presented at the 2026 World Conference on Lung Cancer. “These findings support amivantamab plus chemotherapy as a foundational first-line regimen [in EGFR ex20ins advanced NSCLC],” said study presenter Chul Kim, MD, of Georgetown Cancer Institute in Washington, DC. The data, from the ph
REZILIENT3: Adding Zipalertinib to Chemo Improves PFS in EGFR Exon20ins+ NSCLC (opens the original)
Read excerpt
Adding zipalertinib to chemotherapy improves progression-free survival (PFS) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins), according to findings presented at the 2026 World Conference on Lung Cancer. The tyrosine kinase inhibitor zipalertinib in combination with platinum-based chemotherapy is a new and highly efficacious option for frontline treatment of metastatic EGFR ex20ins-mutant NSCLC, said study pre
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.